Pdt Partners, LLC Astria Therapeutics, Inc. Transaction History
Pdt Partners, LLC
- $1.58 Billion
- Q2 2025
A detailed history of Pdt Partners, LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 54,642 shares of ATXS stock, worth $410,907. This represents 0.02% of its overall portfolio holdings.
Number of Shares
54,642
Previous 28,707
90.34%
Holding current value
$410,907
Previous $153,000
90.85%
% of portfolio
0.02%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding ATXS
# of Institutions
109Shares Held
49.3MCall Options Held
6.6KPut Options Held
0-
Perceptive Advisors LLC New York, NY6.49MShares$48.8 Million1.53% of portfolio
-
Vestal Point Capital, LP New York, NY4.52MShares$34 Million1.28% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.11MShares$30.9 Million6.34% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$26.7 Million5.84% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$26.5 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $114M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...